{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:48Z","timestamp":1759366068415,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.nefro.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T08:05:33Z","timestamp":1577693133000},"page":"414-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seguridad renal de espironolactona en pacientes con hipertensi\u00f3n arterial resistente"],"prefix":"10.1016","volume":"40","author":[{"given":"Isabel","family":"Galceran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Out\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2019.10.004_bib0085","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.10.004_bib0090","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003-2008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.10.004_bib0095","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC Scientific Document Group. 2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefro.2019.10.004_bib0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","article-title":"Refractory hypertension: determination of prevalence, risk factors, and comorbidities in large, population-based cohort","volume":"63","author":"Calhoun","year":"2014","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.10.004_bib0105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"De la Sierra","year":"2011","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.10.004_bib0110","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2019.10.004_bib0115","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"V\u00e1clav\u00edk","year":"2014","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.nefro.2019.10.004_bib0120","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","article-title":"Role of adding spironolactone and renal denervation in true resistant hypertension one-year outcomes of randomized PRAGUE-15 study","volume":"67","author":"Rosa","year":"2016","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.10.004_bib0125","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/HJH.0000000000001025","article-title":"Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial","volume":"34","author":"Oliveras","year":"2016","journal-title":"J Hypertens."},{"key":"10.1016\/j.nefro.2019.10.004_bib0130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effects of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.10.004_bib0135","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and real function","volume":"24","author":"Van den Meiracker","year":"2006","journal-title":"J Hypertens."},{"key":"10.1016\/j.nefro.2019.10.004_bib0140","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.10.004_bib0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rate of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.10.004_bib0150","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefro.2019.10.004_bib0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effects of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease, a nationwide population-base study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.nefro.2019.10.004_bib0160","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951930195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951930195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:54:12Z","timestamp":1759323252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021169951930195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S021169951930195X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.10.004","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seguridad renal de espironolactona en pacientes con hipertensi\u00f3n arterial resistente","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}